• 1
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335340.MEDLINE
  • 2
    Collier DS, Calne R, Thiru S, Lim S, Pollard SG, Barron P, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990; 22:16741675.MEDLINE
  • 3
    Collier DS, Calne RY, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23:22462247.MEDLINE
  • 4
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999; 68:15261532.MEDLINE
  • 5
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments]. Transplantation 1999; 67:10361042.MEDLINE
  • 6
    Chang GJ, Mahanty H, Vincenti F, Freise C, Ascher NA, Roberts JP, et al. Sirolimus provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transpl 2000; In Press.
  • 7
    Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 1999; 68:701704.MEDLINE
  • 8
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:12521260.MEDLINE
  • 9
    Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505509.MEDLINE
  • 10
    Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 1999; 11:967975.MEDLINE
  • 11
    Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, et al. Experience with daclizumab in liver transplantation: Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69:307311.MEDLINE
  • 12
    Chang GJ, O'Rourke R, Lee I, Stock PG, Vincenti F. One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function. American Society of Transplant Physicians, Annual Scientific Meeting; Chicago, IL, May 15–19, 1999 1999;.
  • 13
    Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transpl 2000; 14:97109.
  • 14
    Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20:753761.MEDLINE
  • 15
    Brown RS, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62:17881793.MEDLINE